Filtered By:
Cancer: Carcinoma
This page shows you your search results in order of date.
Order by Relevance | Date
Total 3372 results found since Jan 2013.
NADPH oxidase 4 facilitates progression of chondrosarcoma via generation of reactive oxygen species
Acta Biochim Pol. 2023 Sep 18. doi: 10.18388/abp.2020_6580. Online ahead of print.ABSTRACTNicotinamide adenine dinucleotide phosphate oxidase 4 (NOX4) is an enzyme that regulates reactive oxygen species (ROS) generation, and its function in the development of chondrosarcoma remains unclear. In the present study, we studied NOX4 expression in chondrosarcoma by immunochemical examination, and analyzed the role of NOX4 in viability and apoptosis of human chondrosarcoma cell line SW1353 using NOX4 siRNA or NOX4 inhibitor GKT137831. NOX4 level significantly increased in tumor compared to that in para-carcinoma sample. The level...
Source: Acta Biochim Pol - September 18, 2023 Category: Biochemistry Authors: Zheng Jun Wang Lei Fang Ce Ren Wen Tao Meng Xiang Hui Qing Ci Nan Source Type: research
Knockdown of LIMD2 inhibits the progression of ovarian carcinoma through ERK1/2 pathway
CONCLUSION: Knockdown of LIMD2 inhibits cell proliferation, migration, invasion and autophagy, and promotes the apoptosis through the ERK1/2 signaling pathway, suggesting that LIMD2-siRNA may be an effective molecule to prevent OC progression.PMID:37716918 | DOI:10.1007/s11033-023-08733-6
Source: Mol Biol Cell - September 16, 2023 Category: Molecular Biology Authors: Haiyang Hu Yanan Wang Yan Dong Lin Wang Yahui Chen Yan Zhou Lin Sun Source Type: research
GSE242834 Gene expression profiling and the effect of HDAC9 in cisplatin resistance of esophageal squamous cell carcinoma
Series Type : Non-coding RNA profiling by arrayOrganism : Homo sapiensEsophageal cancer is one of the most serious health problems globally because of its high incidence and mortality rate. Cisplatin(CDDP) is the primary treatment but limited by the drug resistance. However, the mechanism of cisplatin resistance remains unclear. Herein, the CDDP-resistant cell line TE-1/CDDP was established to compared with TE-1, the expression profiles of circRNAs were compared between TE-1/CDDP and TE-1 using microarray analysis, Histone deacetylase 9(HDAC9) was identified significantly up-regulated. Using siRNA and conducting cell funct...
Source: GEO: Gene Expression Omnibus - September 14, 2023 Category: Genetics & Stem Cells Tags: Non-coding RNA profiling by array Homo sapiens Source Type: research
Crosstalk between PD-L1 and Jak2-Stat3/ MAPK-AP1 signaling promotes oral cancer progression, invasion and therapy resistance
CONCLUSIONS: PD-L1 was regulated mainly by the Jak2-Stat3/ MAPK-AP1 pathway, and besides the routine immunological functions, it supports OSCC survival, invasion, and therapy resistance. PD-L1 can be used as an indicator of severity and can be targeted along with Jak2-Stat3/ MAPK-AP1 for a better outcome OSCC.PMID:37678027 | DOI:10.1016/j.intimp.2023.110894
Source: International Immunopharmacology - September 7, 2023 Category: Allergy & Immunology Authors: Arpita Jha Manzar Alam Tanushree Kashyap Nidhi Nath Anjali Kumari Kamdeo K Pramanik Siddavaram Nagini Rajakishore Mishra Source Type: research
Transcription Factor JunB Suppresses Hepatitis C Virus Replication
Kobe J Med Sci. 2023 Aug 31;69(3):E86-E95.ABSTRACTWe previously reported that hepatitis C virus (HCV) infection activates the reactive oxygen species (ROS)/c-Jun N-terminal kinase (JNK) signaling pathway. Activation of JNK contributes to the development of liver diseases, including metabolic disorders, steatosis, liver cirrhosis and hepatocellular carcinoma. JNK is known to have numerous target genes, including JunB, a member of activator protein-1 transcription factor family. However, the roles of JunB in the HCV life cycle and HCV-associated pathogenesis remain unclear. To clarify a physiological role of JunB in HCV infe...
Source: Kobe J Med Sci - September 4, 2023 Category: General Medicine Authors: Adi Ariffianto Lin Deng Saki Harada Yujiao Liang Chieko Matsui Takayuki Abe Ikuo Shoji Source Type: research
